$DRMA
Dermata Therapeutics, Inc.

2021 Q4 Form 10-K Financial Statement

#000165495422003869 Filed on March 28, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.441M $4.398M $377.1K
YoY Change 282.12% 180.99%
% of Gross Profit
Research & Development $1.112M $3.459M $110.0K
YoY Change 910.71% 115.16%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00 $0.00
YoY Change -100.0%
% of Gross Profit
Operating Expenses $2.553M $3.459M $491.4K
YoY Change 419.48% 115.16%
Operating Profit -$7.857M
YoY Change 147.63%
Interest Expense $0.00 $45.61K -$38.48K
YoY Change -100.0% -76.88%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$2.553M -$7.902M -$396.3K
YoY Change 544.16% 144.17%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$2.553M -$7.902M -$396.3K
YoY Change 544.15% 144.17%
Net Earnings / Revenue
Basic Earnings Per Share -$2.43
Diluted Earnings Per Share -$306.5K -$948.8K -$47.58K
COMMON SHARES
Basic Shares Outstanding 8.329M shares 4.302M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.80M $10.80M
YoY Change 1935.97%
Cash & Equivalents $10.80M $530.4K
Short-Term Investments
Other Short-Term Assets $825.1K $825.1K
YoY Change 999.45%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $11.62M $11.62M $605.5K
YoY Change 1819.87% 1819.88%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $11.62M $11.62M $605.5K
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $11.62M $11.62M $605.5K
YoY Change 1819.87% 1819.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $515.2K $515.3K $104.3K
YoY Change 394.12% 394.1%
Accrued Expenses $1.002M $1.002M
YoY Change 650.37%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $0.00 $0.00 $556.2K
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $1.517M $1.517M $3.783M
YoY Change -59.91% -59.91%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.517M $1.517M $3.783M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $1.517M $1.517M $3.783M
YoY Change -59.91% -59.91%
SHAREHOLDERS EQUITY
Retained Earnings -$35.98M -$28.08M
YoY Change 28.14%
Common Stock $833.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $10.11M $10.11M -$3.178M
YoY Change
Total Liabilities & Shareholders Equity $11.62M $11.62M $605.5K
YoY Change 1819.87% 1819.88%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$2.553M -$7.902M -$396.3K
YoY Change 544.15% 144.17%
Depreciation, Depletion And Amortization $0.00 $0.00 $0.00
YoY Change -100.0%
Cash From Operating Activities -$1.804M -$5.693M -$536.0K
YoY Change 236.57% 41.33%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -620.0 $15.96M 313.3K
YoY Change -100.2% 521.77%
NET CHANGE
Cash From Operating Activities -1.804M -$5.693M -536.0K
Cash From Investing Activities
Cash From Financing Activities -620.0 $15.96M 313.3K
Net Change In Cash -1.805M $10.27M -222.6K
YoY Change 710.51% -802.64%
FREE CASH FLOW
Cash From Operating Activities -$1.804M -$5.693M -$536.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
530400 USD
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
825134 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
75053 USD
CY2021Q4 us-gaap Assets Current
AssetsCurrent
11623940 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
605453 USD
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
515245 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
104276 USD
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1001591 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
133477 USD
CY2021Q4 us-gaap Convertible Subordinated Debt
ConvertibleSubordinatedDebt
0 USD
CY2020Q4 us-gaap Convertible Subordinated Debt
ConvertibleSubordinatedDebt
1848495 USD
CY2021Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
0 USD
CY2020Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
1140984 USD
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 USD
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
556160 USD
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1516836 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3783392 USD
CY2021Q4 us-gaap Liabilities
Liabilities
1516836 USD
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10798806 USD
CY2021 dei Auditor Location
AuditorLocation
San Diego, California
CY2020Q4 us-gaap Liabilities
Liabilities
3783392 USD
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8328629 shares
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
833 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
0 USD
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
46088546 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
0 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-35982275 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-28079798 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
10107104 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-3177939 USD
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11623940 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
605453 USD
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3459340 USD
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1607819 USD
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4397524 USD
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1565034 USD
CY2021 us-gaap Proceeds From Securitizations Of Loans Held For Investment
ProceedsFromSecuritizationsOfLoansHeldForInvestment
0 USD
CY2020 us-gaap Proceeds From Securitizations Of Loans Held For Investment
ProceedsFromSecuritizationsOfLoansHeldForInvestment
133592 USD
CY2021 us-gaap Interest Expense
InterestExpense
45613 USD
CY2021 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
14126 USD
CY2020 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
97104 USD
CY2021 us-gaap Depreciation Expense On Reclassified Assets
DepreciationExpenseOnReclassifiedAssets
0 USD
CY2020 us-gaap Depreciation Expense On Reclassified Assets
DepreciationExpenseOnReclassifiedAssets
322 USD
CY2021 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
7856864 USD
CY2020 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
3172853 USD
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-7856864 USD
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-3172853 USD
CY2020 us-gaap Interest Expense
InterestExpense
197269 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-7902477 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-3236530 USD
CY2021 drma Deemed Dividend Upon The Redemption Of Preferred Stock
DeemedDividendUponTheRedemptionOfPreferredStock
269038 USD
CY2020 drma Deemed Dividend Upon The Redemption Of Preferred Stock
DeemedDividendUponTheRedemptionOfPreferredStock
0 USD
CY2021 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
2293199 USD
CY2020 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
0 USD
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10464714 USD
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3236530 USD
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.43
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.69
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4302232 shares
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1911009 shares
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-210159 USD
CY2020 drma Series Preferred Units Issued Amount
SeriesPreferredUnitsIssuedAmount
250000 USD
CY2020 drma Exercise Of Series1a Preferred Warrant Units Amount
ExerciseOfSeries1aPreferredWarrantUnitsAmount
18750 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-3236530 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-3177939 USD
CY2021 drma Series1d Preferred Units Issued Amount
Series1dPreferredUnitsIssuedAmount
5034801 USD
CY2021 drma Class B Common Units Forfeited Amount
ClassBCommonUnitsForfeitedAmount
0 USD
CY2021 drma Conversion Of Common Units To Common Stock Amount
ConversionOfCommonUnitsToCommonStockAmount
0 USD
CY2020 drma Class B Common Units Issued Amount
ClassBCommonUnitsIssuedAmount
-1000000 USD
CY2021 drma Conversion Of Preferred Units To Preferred Stock Amount
ConversionOfPreferredUnitsToPreferredStockAmount
0 USD
CY2021 drma Conversion Of Warrant Units To Preferred Stock Amount
ConversionOfWarrantUnitsToPreferredStockAmount
0 USD
CY2021 drma Conversion Of Convertible Debt To Common Stock Amount
ConversionOfConvertibleDebtToCommonStockAmount
180434 USD
CY2021 drma Issuance Of Common Stock And Warrants Net Issuance Costs Amount
IssuanceOfCommonStockAndWarrantsNetIssuanceCostsAmount
15385563 USD
CY2021 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
1586722 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-7902477 USD
CY2021 drma Conversion Of Preferred Stock To Common Stock Amount
ConversionOfPreferredStockToCommonStockAmount
0 USD
CY2021 drma Conversion Of Preferred Stock Warrants To Common Stock Warrants Amount
ConversionOfPreferredStockWarrantsToCommonStockWarrantsAmount
0 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
10107104 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-7902477 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-3236530 USD
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
1905408 USD
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
0 USD
CY2021 us-gaap Proceeds From Collection Of Other Loans Held For Sale
ProceedsFromCollectionOfOtherLoansHeldForSale
0 USD
CY2020 us-gaap Proceeds From Collection Of Other Loans Held For Sale
ProceedsFromCollectionOfOtherLoansHeldForSale
133592 USD
CY2021 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-750081 USD
CY2020 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1374 USD
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
410969 USD
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-232908 USD
CY2021 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
628663 USD
CY2020 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-21563 USD
CY2021 drma Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts
15385563 USD
CY2020 drma Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts
0 USD
CY2021 drma Redemption Of Series1 C Preferred Stock
RedemptionOfSeries1CPreferredStock
1000000 USD
CY2020 drma Redemption Of Series1 C Preferred Stock
RedemptionOfSeries1CPreferredStock
0 USD
CY2021 us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
-556482 USD
CY2020 us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
-810185 USD
CY2021 us-gaap Proceeds From Loan Originations1
ProceedsFromLoanOriginations1
0 USD
CY2020 us-gaap Proceeds From Loan Originations1
ProceedsFromLoanOriginations1
133592 USD
CY2021 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1562717 USD
CY2020 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
2974982 USD
CY2021 drma Increase Decrease In License And Settlement Agreement
IncreaseDecreaseInLicenseAndSettlementAgreement
0
CY2020 drma Increase Decrease In License And Settlement Agreement
IncreaseDecreaseInLicenseAndSettlementAgreement
500,000
CY2021 us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
2209085 USD
CY2020 us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
-792011 USD
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5693392 USD
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4028541 USD
CY2021 drma Proceeds From Issuance Of Series1 D Preferred Units
ProceedsFromIssuanceOfSeries1DPreferredUnits
570000 USD
CY2020 drma Proceeds From Issuance Of Series1 D Preferred Units
ProceedsFromIssuanceOfSeries1DPreferredUnits
0 USD
CY2021 drma Net Proceeds From Issuance Of Series1 C Preferred Units
NetProceedsFromIssuanceOfSeries1CPreferredUnits
0 USD
CY2020 drma Net Proceeds From Issuance Of Series1 C Preferred Units
NetProceedsFromIssuanceOfSeries1CPreferredUnits
250000 USD
CY2021 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
0 USD
CY2020 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
18750 USD
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15961798 USD
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2567139 USD
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
10268406 USD
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1461402 USD
CY2020Q4 us-gaap Cash
Cash
530400 USD
CY2019Q4 us-gaap Cash
Cash
1991802 USD
CY2020Q4 us-gaap Cash
Cash
530400 USD
CY2021 us-gaap Interest Paid
InterestPaid
1420 USD
CY2020 us-gaap Interest Paid
InterestPaid
56707 USD
CY2021 us-gaap Income Taxes Paid
IncomeTaxesPaid
1400 USD
CY2020 us-gaap Income Taxes Paid
IncomeTaxesPaid
3272 USD
CY2021 drma Conversion Of Common And Preferred Units And Warrants To Common And Preferred Stock And Warrants
ConversionOfCommonAndPreferredUnitsAndWarrantsToCommonAndPreferredStockAndWarrants
29936660 USD
CY2020 drma Conversion Of Common And Preferred Units And Warrants To Common And Preferred Stock And Warrants
ConversionOfCommonAndPreferredUnitsAndWarrantsToCommonAndPreferredStockAndWarrants
0 USD
CY2021 drma Conversion Of Convertible Subordinated Promissory Notes To Series1 D Preferred Units
ConversionOfConvertibleSubordinatedPromissoryNotesToSeries1DPreferredUnits
4464801 USD
CY2020 drma Conversion Of Convertible Subordinated Promissory Notes To Series1 D Preferred Units
ConversionOfConvertibleSubordinatedPromissoryNotesToSeries1DPreferredUnits
0 USD
CY2021 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
2293199 USD
CY2020 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
0 USD
CY2021 us-gaap Interest Expense Subordinated Notes And Debentures
InterestExpenseSubordinatedNotesAndDebentures
180434 USD
CY2020 us-gaap Interest Expense Subordinated Notes And Debentures
InterestExpenseSubordinatedNotesAndDebentures
0 USD
CY2021 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
6582 USD
CY2020 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0 USD
CY2021Q3 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
2571428 shares
CY2021Q3 drma Combined Offering Price
CombinedOfferingPrice
7 shares
CY2021Q3 drma Warrants To Purchase One Share Of Common Stock
WarrantsToPurchaseOneShareOfCommonStock
2957142 shares
CY2021Q3 us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
65823015 shares
CY2021Q3 drma Common Stock At An Exercise Price
CommonStockAtAnExercisePrice
7
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8328629 shares
CY2021Q4 drma Accumulated Deficit
AccumulatedDeficit
-36000000 USD
CY2021 us-gaap Net Cash Provided By Used In Discontinued Operations
NetCashProvidedByUsedInDiscontinuedOperations
5700000 USD
CY2020 us-gaap Net Cash Provided By Used In Discontinued Operations
NetCashProvidedByUsedInDiscontinuedOperations
4000000 USD
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:left;">The Company’s financial statements are prepared in accordance with GAAP. The preparation of the Company’s financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, and expenses and disclosure of contingent assets and liabilities in the financial statements and accompanying notes. On an ongoing basis, management evaluates these estimates and judgments, including those related to accrued research and development expenses, stock-based compensation, and the estimated fair values of equity instruments. Management evaluates its estimates on an ongoing basis. The Company bases its estimates on various assumptions that it believes are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.</p>
CY2021Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
2600000 USD
CY2021Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
60000.00 USD
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
0 USD
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
322 USD
CY2021 drma Schedule Of Potentially Dilutive Securities
ScheduleOfPotentiallyDilutiveSecurities
<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>As of December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series 1 Preferred Units/Shares</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">336,882</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series 1a Preferred Units/Shares</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">244,811</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series 1a Preferred Warrant </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">69,212</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series 1b Preferred Units/Shares</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">317,058</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series 1c Preferred Units/Shares</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,270,866</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series 1d Preferred Units/Shares</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Class B Common Units Profits Interests</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">365,245</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Common Stock Options</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">523,199</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Common Stock Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,091,657</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total potentially dilutive securities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3,614,856</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3,604,074</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2020Q4 drma Series1 Preferred Units Shares
Series1PreferredUnitsShares
336882 shares
CY2020Q4 drma Series1 A Preferred Units Shares
Series1APreferredUnitsShares
244811 shares
CY2020Q4 drma Series1 A Prerferred Warrant Units Shares
Series1APrerferredWarrantUnitsShares
69212 shares
CY2020Q4 drma Series1 B Preferred Units Shares
Series1BPreferredUnitsShares
317058 shares
CY2020Q4 drma Series1 C Preferred Units Shares
Series1CPreferredUnitsShares
2270866 shares
CY2020Q4 drma Class B Common Units Profits Interests
ClassBCommonUnitsProfitsInterests
365245 shares
CY2021Q4 drma Common Stock Options
CommonStockOptions
523199 shares
CY2021Q4 drma Common Stock Warrants
CommonStockWarrants
3091657 shares
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3614856 shares
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3604074 shares
CY2020Q4 us-gaap Convertible Subordinated Debt
ConvertibleSubordinatedDebt
3000000 USD
CY2020Q4 us-gaap Notes Payable
NotesPayable
1145000 USD
CY2020Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
1730000 USD
CY2020Q4 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
125000 USD
CY2020Q4 us-gaap Subordinated Borrowing Interest Rate
SubordinatedBorrowingInterestRate
0.04 pure
CY2020Q4 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2021-07-17
CY2021Q1 drma Discount Rate For Preferred Shares
DiscountRateForPreferredShares
10000000 USD
CY2021Q1 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2021-12-31
CY2021Q1 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
1255000 USD
CY2021Q1 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
311000 USD
CY2021 drma Unrecognized Future Stock Based Compensation Expense
UnrecognizedFutureStockBasedCompensationExpense
1200000 USD
CY2021 drma Expected Lenght Of Recognized Term
ExpectedLenghtOfRecognizedTerm
P2Y9M18D
CY2019Q2 us-gaap Debt Instrument Fee Amount
DebtInstrumentFeeAmount
100000 USD
CY2021Q1 us-gaap Debt Instrument Fee Amount
DebtInstrumentFeeAmount
100000 USD
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8328629 shares
CY2021Q4 drma Common Stock Share Issued
CommonStockShareIssued
6906244 shares
CY2021 drma Preferred Unit Interest Rate
PreferredUnitInterestRate
8
CY2021Q4 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
0.80
CY2021Q2 drma Common Stock Shares Available For Issuances
CommonStockSharesAvailableForIssuances
593340 shares
CY2021Q3 drma Common Stock Shares Available For Issuances
CommonStockSharesAvailableForIssuances
1648213 shares
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000 shares
CY2021Q4 drma Outstanding Warrants Exercisable
OutstandingWarrantsExercisable
2957142 shares
CY2021Q4 drma Warrants Fair Value Per Share
WarrantsFairValuePerShare
1.74
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2957142 shares
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
7
CY2021 drma Warrants Expire Date
WarrantsExpireDate
August 17, 2026
CY2021Q1 drma Class B Common Units Profits Interests Converted Due To The Conversion From An Llc To Ac Corporation
ClassBCommonUnitsProfitsInterestsConvertedDueToTheConversionFromAnLlcToACCorporation
277448 shares
CY2021Q1 drma Class B Common Units Profits Interests Converted Into Options
ClassBCommonUnitsProfitsInterestsConvertedIntoOptions
277448 shares
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1339993 USD
CY2019Q2 us-gaap Preferred Units Issued
PreferredUnitsIssued
5221156 shares
CY2021 drma Additional Research And Development Expense
AdditionalResearchAndDevelopmentExpense
2100000 USD
CY2020Q4 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
1145000 USD
CY2021 us-gaap Convertible Preferred Stock Converted To Other Securities
ConvertiblePreferredStockConvertedToOtherSecurities
1255000 USD
CY2021 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
2300000 USD
CY2021 drma Dividends Preferred Stock D4
DividendsPreferredStockD4
1200000 USD
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1659000 USD
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
0 USD
CY2021 drma Income Tax Reconciliation Permanent And Other Difference
IncomeTaxReconciliationPermanentAndOtherDifference
38000 USD
CY2020 drma Income Tax Reconciliation Permanent And Other Difference
IncomeTaxReconciliationPermanentAndOtherDifference
0 USD
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
110000 USD
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
0 USD
CY2021 drma Income Tax Reconciliation Taxes Credits Research
IncomeTaxReconciliationTaxesCreditsResearch
-118000 USD
CY2020 drma Income Tax Reconciliation Taxes Credits Research
IncomeTaxReconciliationTaxesCreditsResearch
0 USD
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1629000 USD
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
0 USD
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
1049000 USD
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
0 USD
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
118000 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
0 USD
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
274000 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
0 USD
CY2021Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
110000 USD
CY2020Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
0 USD
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
78000 USD
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
0 USD
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
1629000 USD
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
0 USD
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1629000 USD
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
0 USD
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2021Q4 drma Valuation Allowance
ValuationAllowance
1600000 USD
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
5000000.0 USD
CY2021Q4 drma Net Operating Loss Carryforwards Taxable Income Offset Limit Percentage
NetOperatingLossCarryforwardsTaxableIncomeOffsetLimitPercentage
0.80 pure
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
41000 USD
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
0 USD
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
0 USD
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
0 USD
CY2021 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
0 USD
CY2020 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
0 USD
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
41000 USD
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD

Files In Submission

Name View Source Status
0001654954-22-003869-index-headers.html Edgar Link pending
0001654954-22-003869-index.html Edgar Link pending
0001654954-22-003869.txt Edgar Link pending
0001654954-22-003869-xbrl.zip Edgar Link pending
drma-20211231.xsd Edgar Link pending
drma-20211231_cal.xml Edgar Link unprocessable
drma-20211231_def.xml Edgar Link unprocessable
drma-20211231_lab.xml Edgar Link unprocessable
drma-20211231_pre.xml Edgar Link unprocessable
drma_10k.htm Edgar Link pending
drma_10kimg1.jpg Edgar Link pending
drma_10kimg10.jpg Edgar Link pending
drma_10kimg2.jpg Edgar Link pending
drma_10kimg3.jpg Edgar Link pending
drma_10kimg4.jpg Edgar Link pending
drma_10kimg5.jpg Edgar Link pending
drma_10kimg6.jpg Edgar Link pending
drma_10kimg7.jpg Edgar Link pending
drma_10kimg8.jpg Edgar Link pending
drma_10kimg9.jpg Edgar Link pending
drma_10k_htm.xml Edgar Link completed
drma_ex231.htm Edgar Link pending
drma_ex311.htm Edgar Link pending
drma_ex312.htm Edgar Link pending
drma_ex321.htm Edgar Link pending
drma_ex46.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending